July 2nd 2024
The manufacturer has resubmitted an application to the FDA for approval of the drug cosibelimab, which is being investigated for the treatment of metastatic or locally advanced cutaneous squamous cell carcinoma.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Findings for the Combination of Anti-TIM-3 and Anti-PD-1 in Melanoma and Lung Cancer
December 27th 2018Diwakar Davar, MBBS, MSc, discusses how data from the phase I trial of TSR-022, an anti-TIM-3 monoclonal antibody, and TSR-042, an anti-PD-1 agent, impact the treatment of patients with both melanoma and lung cancer.
Watch
Quantifying the Benefits of Precision Oncology
December 14th 2018Precision medicine has produced some dramatic successes in patients with advanced cancer. With developments in molecular profiling, targeted therapies are being applied to multiple tumors, most notably in advanced melanoma, NSCLC, and several types of leukemia. Alison Schram, MD, and David M. Hyman, MD, point out the challenges in determining the proportion of patients who will benefit from receiving targeted therapies.
Read More
Cemiplimab May Hold Promise in Advanced Basal Cell Carcinoma
December 12th 2018Patients with advanced basal cell carcinoma who experience progression on hedgehog pathway inhibitor therapy, or are intolerant to it, have no approved therapeutic options. An ongoing phase II study evaluating cemiplimab in this population may prove efficacious based on its activity in other advanced malignancies.
Read More